Dec 09, 2019
Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations
Dec 09, 2019
Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting
Jun 25, 2019
Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019
Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
May 09, 2019
Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Dec 04, 2018
New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the American Epilepsy Society (AES)
Nov 21, 2018
Eisai To Present FYCOMPA Long-Term Sustained Seizure Freedom And Pediatric Data At Upcoming American Epilepsy Society Annual Meeting
Oct 24, 2018
Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
Sep 28, 2018
Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
May 30, 2018
Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)
Apr 19, 2018
Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA
Mar 30, 2018
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications
Feb 05, 2018
Embrace by Empatica is the world's first smart watch to be cleared by FDA for use in Neurology
Dec 05, 2017
Child Neurology Foundation and Eisai Announce New Transitions of Care Resources for Young People Living with Epilepsy
Nov 22, 2017
Eisai Announces Presentations on Perampanel (marketed as FYCOMPA CIII) at the Annual Meeting of the American Epilepsy Society (AES)
Jul 26, 2017
FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures